Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Visx

This article was originally published in The Gray Sheet

Executive Summary

Visx: Excimer laser manufacturer says it will report higher than predicted fourth-quarter 1997 earnings, following a Dec. 16 announcement that the firm has stopped making certain royalty payments to Pillar Point Partners, a joint venture with laser maker Summit Technology. "Commencing in October 1997, the company no longer pays royalties to Pillar Point for certain patented procedures performed using the Visx excimer laser system which have not been approved by FDA," Visx explains. "This is consistent with a provision in the agreement which provides that royalties are due only for FDA-approved procedures." A November lawsuit filed by Visx in a Santa Clara County, California state court seeking declaratory judgment is pending...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel